Kumar A, Ramanan Siddharth V, Carollo Brett, Swanson Kristen, Parikh Raj
Department of Internal Medicine University of Connecticut School of Medicine Farmington Connecticut USA.
Division of Pulmonary, Critical Care and Sleep Hartford Hospital Hartford Connecticut USA.
Pulm Circ. 2025 Jul 2;15(3):e70111. doi: 10.1002/pul2.70111. eCollection 2025 Jul.
PH-ILD carries a poor prognosis, particularly with PVR > 5 WU. The INCREASE trial demonstrated the successful use of inhaled treprostinil, but slow uptitration delays the effects. Our study suggests outpatient IV dobutamine as interim support, improving contractility and reducing PVR during uptitration.
PH-ILD预后较差,尤其是在肺血管阻力(PVR)>5伍德单位(WU)时。INCREASE试验证明吸入用曲前列尼尔的使用是成功的,但滴定速度缓慢会延迟疗效。我们的研究表明,门诊静脉注射多巴酚丁胺作为过渡支持,可在滴定过程中改善收缩力并降低PVR。